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Abstract
Genetic susceptibility is an important contributor to the pathogenesis of Crohn’s disease (CD). We investigated multiple CD
susceptibility genes in an Australian paediatric onset CD cohort. Newly diagnosed paediatric onset CD patients (n=72) and
controls (n=98) were genotyped for 34 single nucleotide polymorphisms (SNPs) in 18 genetic loci. Gene-gene interaction
analysis, gene-disease phenotype analysis and genetic risk profiling were performed for all SNPs and all genes. Of the 34
SNPs analysed, four polymorphisms on three genes (NOD2, IL23R, and region 3p21) were significantly associated with CD
status (p,0.05). All three CD specific paediatric polymorphisms on PSMG1 and TNFRSF6B showed a trend of association with
p,0.1. An additive gene-gene interaction involving TLR4, PSMG1, TNFRSF6B and IRGM was identified with CD. Genes
involved in microbial processing (TLR4, PSMG1, NOD2) were significantly associated either at the individual level or in gene-
gene interactive roles. Colonic disease was significantly associated with disease SNP rs7517847 (IL23R) (p,0.05) and colonic
and ileal/colonic disease was significantly associated with disease SNP rs125221868 (IBD5) and SLC22A4 & SLC22A4/5 variants
(p,0.05). We were able to demonstrate genetic association of several genes to CD in a paediatric onset cohort. Several of
the observed associations have not been reported previously in association with paediatric CD patients. Our findings
demonstrate that CD genetic susceptibility in paediatric patients presents as a complex interaction between numerous
genes.
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Introduction
Crohn’s disease (CD) is a chronic relapsing inflammatory
disease occurring anywhere in the gastrointestinal tract, although
it most commonly affects the small intestine [1]. CD is a major
cause of morbidity throughout the world with an escalating
epidemic of CD recorded globally in children and adults during
the past few decades [2]. A worldwide study reported an incidence
per 100,000 population as low as 0.3 in China to as high as 20.2
cases in Canada [2]. A ten-fold increase in the incidence of
paediatric CD over a 31 year period was reported from the Royal
Children’s Hospital (RCH) in Melbourne, Australia [3]. Approx-
imately 30 new cases of CD in children (age 2–16 years) are now
diagnosed and treated at the RCH each year compared with
approximately 3 new cases reported annually in 1975. European
studies report a similar dramatic increase in the incidence of
paediatric CD [4,5]. It is widely accepted that CD is mediated by a
dysfunctional immunological response of T-lymphocytes which is
primarily induced in genetically susceptible individuals by the
presence of an environmental stimulus [6,7].
Genetic factors that affect susceptibility to CD have been
identified using genetic linkage and population based association
studies. Genetic susceptibility to CD has been extensively studied
since the identification of the first CD susceptibility gene NOD2
[8,9]. The NOD gene family is proposed to function as an
intracellular pattern-recognition receptor that senses microbial
muramyl dipeptide, a degradation product of peptidoglycan from
bacterial cell wall and the function of a cytosolic sensor for the
induction of apoptosis [10]. In the last decade several genome-
wide association studies (GWAS) have discovered an increasing
number of novel genes and single nucleotide polymorphisms
(SNPs) associated with CD, including 21 novel loci identified in
2008 alone [11].
Paediatric-onset CD patients have a higher rate of gene
mutations compared with adult patients [12]. Three mutations
were reported to be specifically associated with paediatric-onset
inflammatory bowel disease. One of these (rs2836878) resides in a
region that harbours no gene, but is most closely located to the
proteasome assembly chaperone 1 gene (PSMG1). The other two
SNPs (rs4809330 and rs2315008) are located within a region
containing several genes including the tumour necrosis factor
receptor superfamily member 6B gene (TNFRSF6B) [13]. All three
paediatric specific CD mutations were recently confirmed to be
associated with CD in a Canadian study [14].
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15376The large number of genetic variants implicated in CD requires
multiple SNPs to be investigated simultaneously in CD patients to
understand the individual contributions of loci in single genes and
gene-gene interactions. In our study we investigated the occur-
rence of 34 SNPs simultaneously in a paediatric onset CD cohort.
Results
Hardy-Weinberg equilibrium testing
Three SNPs (rs2836878, rs2066845 and rs5743289 present on
PSMG1 and NOD2) were found to deviate from Hardy Weinberg
Equilibrium (HWE) at the P=0.05 level. However, these SNPs
were retained in the analyses as in each case the deviation from
HWE was observed in the cases only. Such distortions in case
genotype frequency can be an indication of association [15,16].
Thus, alleles and genotypes from all SNPs were compared
between the case and control phenotypic groups.
Genotype and allele frequencies
All SNPs were initially analysed using allelic and genotypic x
2
tests (Table S 1). For SNPs where the minor allele homozygote
counts were less than 5 (rs11209026, rs3792876, rs13361189,
rs6958571, rs17327442, rs4986790, rs2241136, rs2289310,
rs1248696, rs1793004, rs3135932, rs2066844, rs2066845,
rs5743289, rs5743293, rs2836878), we applied Fisher’s exact test
to obtain a genotypic P value. Four SNPs, rs2066845 and
rs5743289 on NOD2 gene, rs11209026 on IL23R gene, and
rs9858542 on region 3p21, demonstrated evidence of association
with CD (Table 1 and Table S1).
a) Additive and genotypic logistic regression
analyses. At the individual level, allelic x
2 and genotypic
Fisher’s comparisons of SNP rs2066845 (NOD2) were highly
significant at p,0.05 (p=0.00016, 0.0076 respectively). However,
no minor allele homozygotes or heterozygotes were observed for
controls, and therefore further analyses by logistic regression were
not performed for this SNP.
Allelic x
2 and genotypic Fisher’s comparisons of SNP rs5743289
(NOD2) were significant at p,0.05 (p=0.027, 0.0088 respectively).
This SNP remained associated by additive, but not genotypic,
logistic regression (Additive: OR=1.9; 95% CI 1.1, 3.3; p=0.020,
Genotypic (2df): p=0.998; OR for heterozygotes compared with
major allele homozygotes=1.02; 95% CI 0.49, 2.1 (p=0.952), no
minor allele homozygotes observed in controls).
Allelic x
2 and genotypic Fisher’s comparisons of SNP
rs11209026 (IL23R) were significant at the p,0.05 level
(p=0.025, 0.023 respectively). This SNP remained associated by
Table 1. Genotypic distribution of CD associated genetic variants.
Gene-SNP Genotype CD Controls P=X
2 or F* OR (95% CI)
NOD2 n% n%
rs2066845 GG 64 89 98 100
CG+CC 8 11 0 0 0.00081*
rs5743289 CC 42 59 65 66
CT 20 28 33 34
TT 9 13 0 0 0.00039*
Main NOD2 n% n%
GG/CC/DEL 51 72 87 89
20 28 11 11 0.005 3.12 (1.39–6.90)
IL23R n% n%
rs11209026 GG 68 94 83 85
AG 3 6 15 15 0.023* 0.325 (0.11–0.98)
A A 00 00
3p21 n % n %
rs9858542 GG 24 34 56 57
GA+AA 46 66 42 43 0.003* 2.56 (1.36–4.81)
PSMG1 n% n%
rs2836878 GG 32 46 55 59
AG+AA 38 54 38 41 0.089 1.72 (0.92–3.21)
TNFRSF6B n% n%
rs4809330 GG 40 56 42 43
AG+AA 31 44 56 57 0.083 1.72 (0.93–3.18
rs2315008 GG 40 56 42 43
GT+TT 30 44 56 57 0.068 1.78 (0.96–3.30)
Four SNPs on three genes (NOD2, IL23R and 3p21 region) were significantly associated with paediatric onset Crohn’s disease (CD) (p,0.05). Main NOD2 variants=SNP
rs2066845, SNP rs2066844, rs5743293. Three SNPs on two paediatric specific CD susceptibility genes (PSMG1 and TNFRSF6B) showed a trend of association (p,0.1),
X
2=Pearson Chi Square analysis, F=Fisher’s exact test analysis, OR=odds ratio, CI=confidence interval.
doi:10.1371/journal.pone.0015376.t001
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p=0.045). Genotypic logistic regression was not performed due
to the lack of minor allele homozygotes.
Allelic and genotypic x
2 comparisons of SNP rs9858542 on
region 3p21 were significant at the p,0.05 level (p=0.021, 0.010
respectively). This SNP remained associated by additive and
genotypic logistic regression (Additive: OR=1.8; 95% CI 1.1–2.9;
p=0.02, Genotypic (2df): p=0.0087).
b) Further analyses. Further analyses were performed by
comparing the disease associated allele distribution between CD
patients and controls (Table 1). Eleven percent of CD patients had
at least one disease-associated allele of SNP rs2066845 (NOD2)
compared to none in the control group (p=0.00081). Thirteen
percent of CD patients had both disease associated alleles of SNP
rs5743289 (NOD2) compared to none in the control group
(p=0.00039). Analysis of all 3 main NOD2 variants (rs2066845,
rs2066844, and rs5743293) revealed that 28% of CD patients had
at least one NOD2 variant compared to 11% in the control group
(OR=3.1, 95% CI 1.39–6.9, p=0.005). One patient had a triple
mutation in the NOD2 gene (heterozygote for rs2066844 and
rs5743293 and homozygote for rs5743289). Three patients had a
double mutation in the NOD2 gene and four patients had a single
mutation in the NOD2 gene. Sixty six percent of CD patients had
at least one disease associated allele of SNP 9858542 (3p21)
compared to 43% in the control group (OR=2.56, 95% CI 1.36–
4.81, p=0.003).
Three SNPs on paediatric specific CD susceptibility genes
(rs2836878 on PSMG1 and rs4809330 and rs2315008 on
TNFRSF6B) demonstrated some evidence of association at the
p,0.1 level of significance. Fifty four percent of CD patients had
at least one disease associated allele of SNP rs2836878 (PSMG1)
compared to 41% in the control group (p=0.089). Disease
associated alleles of SNPs rs4809330 and rs2315008 (TNFRSF6B)
were observed at lower frequency in CD (44%) patients compared
to 57% in the control group (p=0.083 and p=0.068 for
rs4809330 and rs2315008, respectively).
Gene-gene interaction
Several significant gene-gene interactions were detected for all
three disease associated genes (Tables S2a–S2d). There was an
under-representation of wildtype allele combinations in CD
patients compared to controls harbouring gene combinations of
the main NOD2 variants with four other genetic variants (PSMG1,
NOD2 rs5753289, TLR4, and 3p21 (Figure 1). There was an
under-representation of wildtype allele combinations in CD
patients compared to controls harbouring gene combinations of
3p21 variants with four other genetic variants (PSMG1, NOD2
rs5753289, TLR4, and IRGM) (Figure 1). Interestingly, PSMG1,
TLR4, and IRGM were not associated individually with paediatric
CD. Conversely, wildtype allele combinations of TNFRSF6B
variants with NOD2 rs5743289 or IL23R rs11209026 variants were
significantly higher in CD patients compared to controls (Figure 1).
Genotype-Phenotype interaction
The stratification of CD patients according to phenotype is
outlined in Table 2. The majority of patients (76%) had ileal/
colonic disease with or without upper gastrointestinal tract
involvement. We also looked for possible correlation between
genotype and disease location and disease behaviour (Table
S3). Four disease SNPs from three genes had significant
association with disease location. Disease SNP rs7517847
(IL23R) was found more often in CD patients with colonic
Figure 1. Gene-gene interaction analysis of significant CD associated genes. Percent values represent the proportion of wildtype gene-
gene combination. Four wildtype genes were detected in combinations with main NOD2 wildtype and 3p21 wildtype significantly more often in
controls compare to CD patients. TNFRSF6B wildtype gene was detected in combination with wildtype SNP rs5743289 (NOD2) and wildtype SNP
rs11209026 (IL23R) significantly more often in CD patients compared to controls. All differences between CD and controls were significant at P,0.05.
doi:10.1371/journal.pone.0015376.g001
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of this SNP in the same phenotype (1% (1/69)) (p=0.04) (Table
S3). Disease SNP rs12521868 (IBD5)w a sf o u n dm o r eo f t e ni n
CD patients with colonic and ileal/colonic disease (L26L4 &
L36L4) (69% (47/69)) compared to the wildtype form of this
SNP in the same phenotype (24% (17/69)) (p=0.027) (Table
S3). Disease SNPs rs3792876 and rs1050152 (SLC22A4 &
SLC22A4/5) were found more often in CD patients with
L26L4 & L36L4 phenotype (71% (48/68)) compared to the
wild type form of the SNPs in the same phenotype (22% (15/
69)) (p=0.019) (Table S3).
Genetic risk analysis for CD and control patients
We performed a genetic risk analysis using either all CD SNPs,
or only SNPs associated with disease in this study. Quantitative
analysis of all CD SNPs revealed that the proportions of patients
having 7, 8, 11, 15, 16, 18, 19 and 21 CD associated SNPs were
higher in the CD group than the control group (Figure S1a),
whereas analysis of wildtype alleles revealed that control patients
had 19, 20, 21, 22, 24, and 25 alleles (Figure S1b). However, the
overall difference between CD and controls was not significant.
When taking only disease associated SNPs into consideration
the overall differences in SNPs between CD patients and controls
was significant (p=0.009) (Figure 2). A significantly lower
proportion of CD patients had no disease associated SNPs
compared to controls (15.3% versus 28.6%, p=0.042) whereas,
a significantly higher proportion of CD patients had two disease
associated SNPs compared to controls (34.7% versus 14%,
p=0.002) (Figure 2 and Table 3).
Genetic risk analysis for CD phenotype showed that one and
two SNPs, respectively, were most commonly implicated in
disease location ‘‘L36L4’’ and disease behaviour ‘‘B16P’’
(Figure 3). Location phenotype analysis revealed that
rs9858542 (3p21) SNP was the most common single SNP in the
m o s tc o m m o nl o c a t i o n( L 3 6L4) (63.6%) followed by rs5743289
(NOD2) SNP (27.3%) (Table 4). Together these SNPs also
represented the most commong r o u p i n gw i t h i nt h em o s t
common phenotype L3+L4 (65.2%) (Table 4). Behaviour
phenotype analysis revealed that the rs9858542 (3p21) SNP
was the most common single SNP in the most common behaviour
group (B16P) (50%), this was followed by SNP rs5743289
(NOD2) (40%) (Table 4). Together these SNPs also represented
the most common grouping within the most common behaviour
group (B16P) (71.4%) (Table 4).
Discussion
This study analysed a paediatric-onset CD population for the
prevalence of 34 SNPs present on 18 genes, to investigate their
gene-gene interaction and to perform genetic risk profiling. Four
SNP variants present on NOD2, IL23R and on a 3p21
chromosomal region were significantly associated with our CD
population. At the individual level, these SNPs have been reported
previously, but no studies have investigated their interaction in a
paediatric CD cohort. Three CD specific paediatric SNP variants
present on gene PSMG1 and TNFRSF6B were also included in our
investigation [13] and while none showed a significant association,
all three showed a trend towards association (p,0.1). This
represents the second independent confirmation in a case-control
study of a possible role for these SNPs in development of CD.
There was a higher representation of PSMG1 SNP variant in CD
patients, while a higher representation of TNFRSF6B SNP variants
was observed for controls. The higher representation of
TNFRSF6B SNP variants in controls is in contrast to the original
study and to a Canadian case/control study [13,14]. This study
also demonstrated that a small patient cohort was sufficient for
inferences of CD predisposing gene-gene interactions in associa-
tion with paediatric-onset disease.
Our combined heterozygous/homozygous detection rate of the
main NOD2 variants in CD patients was 28% compared with 11%
in the control group. Previous studies have reported a detection
rate between 11%–41% in CD patients and 3–11% in controls
[12,17,18]. These genetic differences possibly reflect regional and
ethnic differences in study populations, highlighted by the virtual
Table 2. Patient phenotype characteristic.
Disease
location
Patient
number
Disease
behaviour
Patient
number
L164 4 (5.7%) B16P 61 (87.1%)
L26L4 12 (17.1%) B26P 6 (8.6%)
L36L4 53 (75.7%) B36P 3 (4.3%)
L4 1 (1.4%)
L16L4=ileal disease with or without upper gastrointestinal tract (GI)
involvement.
L26L4=colonic disease with or without GI involvement.
L36L4=ileal/colonic disease with or without GI involvement.
L4=upper GI disease.
B16P=inflammatory appearance with or without perininal (P) disease.
B26P=stricturing disease with or without P disease.
B36P=penetrating disease with or without P disease.
doi:10.1371/journal.pone.0015376.t002
Figure 2. Genetic risk profile analysis of disease associated
SNPs between CD patients and controls. The proportion of
patients carrying between none and four diseases associated SNPs was
calculated for the CD and control group. P values were calculated by
Chi Square analysis.
doi:10.1371/journal.pone.0015376.g002
Table 3. Number of disease SNPs associated in CD patients
and controls.
Number of SNPs CD controls
0 11 (15.3%) 28 (28.6%)
1 35 (48.6%) 53 (54.1%)
2 25 (34.7%) 14 (14.3%)
3 1 (1.4%) 3 (3.1%)
doi:10.1371/journal.pone.0015376.t003
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rs5743289 of NOD2 was previously identified in GWA studies
using paediatric and adult cohorts [13,20]. The significant
association of the minor homozygote variant with our CD group
confirms the earlier GWAS findings and strengthens the role of
NOD2 in paediatric CD patients. One patient with a triple
mutation in the NOD2 was a 13 year old girl with a L3+4/B1
phenotype. At the time of initial CD diagnosis she had presented
with oesophagitis, focal active gastritis, granulomatous colitis
consistent with CD in the colon, and chronic active proctitis,
however, the role of NOD2 triple mutation in this multiple disease
presentation is not clear.
IL23R variants were first described in 2006 [21]. In our study
the protective minor A allele of SNP rs11209026 was detected in
15% of controls and in 6% of CD patients. In two previous
paediatric studies, the detection rate was 5.5% and 6% in controls
and 3% and 2% in CD patients [22,23]. Intronic IL23R SNP
variants (rs7517847 and rs1004819) were not associated with our
CD group, which is contrary to the Canadian paediatric study
[22]. However, colonic disease appeared to be significantly more
common in our CD patients with disease associated SNP rs751787
compared to wild type genotype, suggesting that genetic
alterations might play a role in CD phenotypic appearance.
The intronic synonymous SNP rs9858542 on 3p21 in close
proximity to the Basson (BSN) gene was first reported to be
associated with CD by the Welcome Trust Case Control
Consortium [24]. The significant association of the heterozy-
gote/homozygote genotype identified in our study (66% in CD
and 43% in controls) is similar to two other studies (60% and
61.5% in CD and 45% and 52.4% in controls) [25,26]. We also
confirmed the involvement of the minor risk allele (A) as reported
by a German and Spanish study [26] but not detected in a US
paediatric study [27]. The role of synonymous SNPs in CD should
not be underestimated. It was reported that synonymous SNPs can
alter mRNA stability, gene expression or can act in linkage
disequilibrium with other important SNPs [28].
Gene-gene interaction analysis performed by stratification of
disease associated SNPs both within, and between, the candidate
genes examined in this study have revealed some very interesting
findings. In particular the apparent interaction of PSMG1 and
TLR4 with the main NOD2 variants, and PSMG1, TLR4, and
IRGM with 3p21, are of interest because these genes were not
associated individually with paediatric CD in our cohort (Figure 1).
This finding illustrates the complex genetic architecture of CD, in
that it is unlikely to be dependent on a single gene but probably is
polygenic in nature. A number of genes in combination are likely
to affect immunological response and microbial detection, and
hence CD risk.
Several of the identified gene-gene variants have been
implicated in microbial detection and interaction. Best known is
NOD2, the product of which is important for the innate
recognition of bacterial lipopolysaccharides and peptidoglycans
[10,29,30]. TLR4 SNP variant was not associated individually in
our CD cohort. However, its significant gene-gene association with
NOD2 and the lipopolysaccharide-signalling role of cell surface
toll-like receptors [31,32], provides strong evidence of a microbial
role in CD genetically susceptible individuals.
The role of PSMG1 SNP variant which showed a trend towards
an association with CD, and its significant association with NOD2
and 3p21 variants suggests an influence on chaperone-driven
proteasome assembly which is important in degradation of
proteins [33]. Up to a three-fold increase in expression of the
proteasome subunit (LMP2), which plays a role in the formation of
immunoproteasome, has been reported in the inflamed gut of
patients with CD and ulcerative colitis [34,35]. Bacterial
lipopolysaccharides have been shown to trigger the formation of
Figure 3. Genetic risk profile analysis stratified by CD
phenotypes. The proportion of patients carrying between none and
four diseases associated SNPs was stratified by CD phenotype.
L164=ileal disease with or without upper gastrointestinal tract (GI)
involvement, L26L4=colonic disease with or without upper GI
involvement, L36L4=ileal/colonic disease with or without upper GI
involvement, L4=upper GI disease, B16P=inflammatory appearance
with or without perininal disease, B26P=stricturing appearance with
or without perininal disease, B3P=penetrating appearance with
perianal disease.
doi:10.1371/journal.pone.0015376.g003
Table 4. Number of disease SNPs stratified by Crohn’s disease phenotype.
Disease location Disease behaviour
Number of SNPs L1±4L 2 ±L4 L3±L4 L4 B1±PB 2 ±PB 3 ±P
0 1 (1%) 8 (11%) 9 (13%) (43%)
1 4 (6%) 8 (11%) 22 (31%)
A 1 (1%) 30 (43%)
C 3 (4%) 2 (3%)
2 2 (3%) 23 (33%)
B 21 (30%)
D 3 (4%) 1 (1%)
3 1 (1%) 1 (1%)
A=63.6% 3p21, 27.3% NOD2 rs5743289, 9.1% NOD2 rs2066845.
B=65.2% 3p21 and NOD2 rs5743289, 30.4% 3p21 and NOD2 rs2066845, 8.7% 3p21 and IL23R rs11209026.
C=50% 3p21, 40% NOD2 rs5743289, 6.6% NOD2 rs2066845, 3.4% IL23R rs11209026.
D=71.4% 3p21 and NOD2 rs5743289, 23.8% 3p21 and NOD2 rs2066845, 4.8% 3p21 and IL23R rs11209026.
doi:10.1371/journal.pone.0015376.t004
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play a role in the generation of active NF-kappaB subunits [37,38].
The significantly larger double mutation rate of NOD2 and PSMG1
variants in the CD group (60%) compared with the control group
(18%) may also suggest that NOD2 mutations affect NF-kappaB
signalling and PSMG1 mutations may potentiate microbial-
triggered inflammation in CD patients.
IRGM gene expression regulates cellular autophagy of internal-
ized bacteria, a process implicated in CD [39]. Studies have shown
that IRGM gene mutation was not confirmed in children but in
ileal CD in the adult population [40–42]. However, its role in
gene-gene association with 3p21 as identified in our study requires
further evaluation. A recent study reported an association between
3p21 variants and another variant of IRGM gene (rs10000113)
which was not investigated in our study [43].
Another interesting finding of our study is the negative
association of TNFRSF6B mutations with CD. The trend towards
association with controls at the individual level and significant
associations with SNPs rs5743289 (NOD2) and rs11209026 (IL23R)
in controls; point towards a possible role in protection against
development of CD. The role of mutations in tumour necrosis
factor receptor genes in CD is not well known. A case/control
study investigating genetic variants of TNFRSF1A and 1B in
association with the three main NOD2 variants, reported that one
out of two SNPs from each gene was significantly implicated in the
CD cohort [44].
The non-significant differences considering all SNPs, between
CD patients and controls, demonstrate that large genotypic
variation occurs in the general population. As a result, a clear
IBD wildtype genotype is difficult to define, but is rather a mixture
of major homozygote and heterozygote combination.
This study illustrates that an association between the number of
SNPs and disease status can be established. A high occurrence of
SNP rs9858542 (3p21) with ileal/colonic disease and inflamma-
tory behaviour with SNP rs5743289 (NOD2) were identified. Other
studies have been equivocal about the association of rs9858542
with CD phenotype [25,26].
The advantage of this study is that our analysis combined 34
CD susceptibility SNPs in a single paediatric onset cohort. As a
result we report novel findings of associations between disease-
associated SNPs and paediatric CD phenotypes. A limitation of
this study is the relatively small sample size compared to adult
studies. Currently, we are not able to repeat the study by recruiting
another paediatric cohort to confirm our findings.
In conclusion, this study has shown that CD susceptibility genes
are likely act in a complex interactive manner in paediatric-onset
CD. Several genes involved in microbial processing (TLR4,
PSMG1, NOD2) were significantly associated either at the
individual level or synergistically with other genes. A possible
novel protective effect of TNFRSF6B genetic variants, in
combination with two other genes, was suggested however, this
was not confirmed by a larger cohort study [14]. Many of the
genetic interactions identified have not been reported previously.
The results are important to understanding the pathogenesis of
CD, however, need to be confirmed in future studies.
Methods
Study population
In this study 72 paediatric CD patients and 98 paediatric
control patients were analysed. All patients were admitted through
the Department of Gastroenterology at the Royal Children’s
Hospital, Melbourne, Australia. The clinical diagnosis of CD was
established using standard clinical, endoscopic, and histopatho-
logical criteria according to the Montreal classification [45].
Patients in the control group had been admitted for investigation
of symptoms of inflammatory bowel disease (IBD) but were
diagnosed either with gastritis, oesophagitis or no pathological
condition. All the patients were recruited at initial diagnosis. UC
patients were not included in this study due to the low number of
patients available. The mean age in the CD group and control
group were 11.6 years (2.2–17.2) and 11.9 years (1.7–19.8),
respectively. The male/female ratio in the CD group and control
group was 46/26 and 45/53, respectively. The CD phenotype
subgroups are present in Table 2.
Ethics Statement
Ethics approval for the study was obtained from the Human
Research Ethics Committee of the Royal Children’s Hospital
(EHRC no.23003). Written informed consent was obtained from
each individual, parent or guardian prior to enrolment in the
study.
Genotype Analysis
34 SNPs from 18 genes were selected for analysis. The SNPs
and genes were selected from published data that implicated these
SNPs in children and/or adults (Table 5).
Genomic DNA was extracted from gut biopsies or blood
according to protocols in our laboratory [46,47]. The SNP site
flanking regions were retrieved from NCBI SNP reference
assembly database (Build 131). The Sequenom genotyping tools
(www.mysequenom.com) designed PCR amplification, extension
primers and grouped the 34 SNPs into two multiplex assays - 19
multiplex and 16 multiplex assays. The multiplex PCR and
extension reactions were carried out using the Sequenom iPLEX
Gold reaction protocol. Genotyping was performed using the
matrix-assisted laser desorption ionization time-of-flight (MALDI
TOF) mass spectrometry platform [48]. Briefly, the assays were
performed in 5 ml volume and contained 1 ml DNA (10–20ng), 16
PCR buffer, 2mM MgCl2, 500 uM dNTPs, 100nM of PCR
primer mix, 0.5 unit PCR enzyme and nuclease free water. The
PCR cycling conditions were: 94uC for 4 minutes, and 45 cycles at
94uC for 20 seconds, 56uC for 30 seconds, and 72uC for 1 minute,
and a final extension of 72uC for 3 minutes. The second extension
PCR reaction was performed by adding 2 ml iPLEX Gold reaction
mix to the cleaned up primary PCR product. The iPLEX
termination mix contained 0.2 ml iPLEX buffer plus 0.2 ml iPLEX
termination mix, 0.94 ml extension primer mix, 0.041 ml iPLEX
enzyme, and nuclease free water. The iPLEX cycling conditions
were: 94uC for 30 seconds, and 40 cycles at 94uC for 5 seconds
followed by 5 cycles at 52uC for 5 seconds and 80uC for 5 seconds.
The final extension was at 72uC for 3 minutes. The iPLEX Gold
reaction was purified up by adding 16 ml of nuclease free water
and 6 mg resin to each well of the 384 well plates and rotated for
5 minutes and centrifuged at 3200 g for 5 minutes. The products
were then transferred to a Sequenom SpectroCHIP and analysed
on a MALDI-TOF mass spectrometer (Sequenom MassARRAY)
and the SNP calls were viewed using the MassARRAY TYPER
4.05 analyser software. In the majority of SNPs (32/34) a base call
was obtained for at least 99% CD samples and control samples.
Eighty sequencing reactions were performed to retrieve missing
base calls, mainly from the TLR4, NOD2, and DLG5.
Statistical Analyses
Statistical analyses were performed using PLINK version 1.05
statistical software package [49] (http://pngu.mgh.harvard.edu/
,purcell/plink/). Differences between cases and controls were
assessed using allelic and genotypic x
2 analyses. The relationship
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Gene SNP Function (Chr No) 2/2 +/+ +/2 Study
PSMG1 rs2836878 Intron (21) GG AA AG children only [13,14]
TNFRSF6B rs4809330 Intron (20) GG AA AG children only [13,14]
rs2315008 Intron (20) GG TT GT children only [13,14]
NOD2 rs2066844 Missense Arg702Trp (16) CC TT CT children and adult [12],
children [40,51], adult [8,52–
55]
rs2066845 Missense Gly908Arg (16) GG CC CG children [40,51], adult [8,52–
55]
rs5743293 Frame shift Leu1007FsinsC (16) DEL/DEL CC C/DEL children [40,51], adult [8,52–
56]
rs5743289 Intron (16) CC TT CT children [13], adult [20]
NOD1 rs6958571 Intron (7) AA CC CA adult [57]
IL23R rs1004819 Intron (1) CC TT CT children [22], adult [21,58]
7=GW
rs7517847 Intron (1) TT GG GT children [22], children and
adult [59], adult [21,58]
7=GW
rs11209026 Missense Arg381Gln (1) GG AA AG children [22] [27], children
and adult [59], adult [21,58]
7=GW
IL10RA rs2229113 Missense Arg351Gly (11) GG AA AG adult [60]*,
rs3135932 Missense Ser159Gly (11) AA GG GA adult [60]*,
DLG5 rs2289310 Missense Pro1481Gln (10) CC AA CA adult [61]
GW*, adult [61,62],
adult [63]*
rs1248696 Missense Gln140Pro or
Gln140Arg (10)
CC TT TC children and adult [12]*, adult
[62–64]*, adult [61,62]
rs1270912 Intron (10) GG AA AG children and adult [12]*, adult
[61]
GW*
rs2289311 Intron (10) CC TT CT adult [63,64]*, adult [61]
GW,
adult [62]
rs2165047 UTR-3 (10) GG AA AG children and adult [12]**,
adult [61]
GW
rs1344966 (10) AA GG GA adult [61]
GW
IBD5 rs11739135 (5) GG CC GC adult [65–67], children [68]
rs12521868 Intron (5) GG TT GT adult [55,65–67], children [68]
SLC22A4 rs3792876 Intron (5) CC TT TC children and adult [12]***
SLC22A4 rs1050152 Missense Leu503Phe (5) CC TT TC adult [55,67,69]
ATG16L1 rs2241880 Missense Thr281Ala &
Thr300Ala (2)
CC TT CT children [27] [40], children
and adult [59]**, adult [70],
adult [71], adult [72]
GW
IRGM rs13361189 (5) TT CC TC children [27], adult [73]
GW
NKX2-3 rs10883365 (10) GG AA GA children [27], adult [73]
GW,
adult [74–76]
3p21 Basson rs9858542 Intron (3) Synonymous
Thr3912Thr
GG AA GA children [27], adult [26],
children and adult [25].
10q21.1 rs224136 (10) CC TT CT children [27]
TLR4 rs4986790 Missense Asp299Gly (9) AA GG GA children and adult [12]**,
adult [53,54]
NELL1 rs1793004 Intron (11) CC GG CG adult [77], children [27]*
ABCB1 rs17327442 Intron (7) TT AA AT children [78]
MYO9B rs2305764 Intron (19) CC TT TC adult [79]
rs1545620 Missense Ser1011Ala (19) AA CC CA adult [79]
rs962917 Intron (19) CC TT TC adult [79]
Thirty four SNPs from 18 genes were included in this study. (2/2)=major homozygote genotype, (+/+)=minor homozygote genotype, (+/2)=heterozygote genotype,
GW=genome wide association studies, *=no significance reported, **=only reported to be significant and adult, ***=only reported to be significant in children. Chr
No=chromosome number. If not otherwise indicated, all studies described here reported a significant association of the described SNP in either genotype frequency,
allelic frequency or both.
doi:10.1371/journal.pone.0015376.t005
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of association by x
2 testing was also considered using additive and
genotypic regression methods with adjustment for the covariates
age and sex. Gene-gene interaction analysis was calculated using
x
2 analyses. For this the wildtype form (major homozygote) of any
disease associated genes was stratified with wildtype form of all
other genes included in this study. Genotype-phenotype interac-
tion analysis was calculated using Fisher exact test. STATA
version 11 was used for x
2 and Fisher exact test analyses. Where
the number was 5 or below 5 Fisher exact test was used. Multiple
testing adjustments were not performed because the study is in
essence replication of previous studies regarding individual SNPs
(not discovery) (Table 5). This study investigated SNPs that had
been previously associated with CD, significantly reducing the risk
of false positive findings [50].
Supporting Information
Figure S1 Genetic risk profile analysis in CD patients and
controls for all disease associated SNPs. The proportion of patients
carrying between the minimum number (n=7) and maximum
number of CD associated SNPs (n=21) were calculated for the
CD and control group (Figure S1a). Genetic risk profile analysis in
CD patients and controls for all wildtype SNPs. The proportion of
patients carrying between the minimum number (n=12) and
maximum number of wildtype SNPs (n=27) were calculated for
the CD and control group (Figure S1b). (PDF)
Table S1 Genotypic and allelic distribution for all SNPs.
Genotype (GENO) frequencies expressed as minor allele homo-
zygote/heterozygote/major allele homozygote and allele frequen-
cies expressed as minor allele/major allele for all SNPs are
outlined. (PDF)
Table S2 Gene-gene interaction with main NOD2 variants,
NOD2 rs5743289 variant, with IL23R rs11209026 variant, and
3p21 rs9858542 variant, respectively. (PDF)
Table S3 Genotype frequency in CD cases stratified by CD
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